Zabofloxacin

Drug Profile

Zabofloxacin

Alternative Names: DW-224a; DW224aa; PB-101; Zabofloxacin hydrochloride; Zabolante; Zrumgil

Latest Information Update: 30 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dong Wha
  • Developer Dong Wha Pharmaceutical; IASO Pharma
  • Class Antibacterials; Carboxylic acids; Cyclopropanes; Fluoroquinolones; Naphthyridines; Small molecules
  • Mechanism of Action DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Respiratory tract infections
  • No development reported Community-acquired pneumonia

Most Recent Events

  • 09 Sep 2015 No recent reports on development identified - Phase-II for Community-acquired pneumonia in South Korea (PO, capsule)
  • 01 Aug 2014 Dong Wha completes a phase III trial in Respiratory tract infections in South Korea (NCT01658020) (PO, tablet)
  • 31 Jul 2014 Dong Wha Pharmaceutical initiates enrolment in a phase I trial in Healthy volunteers in South Korea (NCT02212795)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top